United Therapeutics (NASDAQ:UTHR) Shares Down 4.1% on Insider Selling

United Therapeutics Corporation (NASDAQ:UTHR)’s share price fell 4.1% on Friday after an insider sold shares in the company. The stock traded as low as $547.63 and last traded at $548.1420. Approximately 122,396 shares were traded during trading, a decline of 77% from the average session volume of 535,885 shares. The stock had previously closed at $571.38.

Specifically, CEO Martine Rothblatt sold 7,580 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $517.97, for a total transaction of $3,926,212.60. Following the transaction, the chief executive officer owned 326,363 shares in the company, valued at approximately $169,046,243.11. This represents a 2.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine Rothblatt sold 1,920 shares of United Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $550.22, for a total transaction of $1,056,422.40. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $178,515,027.46. This represents a 0.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In other news, EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $564.95, for a total transaction of $4,689,085.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $25,519,921.40. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. The Goldman Sachs Group initiated coverage on United Therapeutics in a research note on Thursday, September 24th. They issued a “sell” rating and a $321.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of United Therapeutics in a report on Thursday. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $621.00.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: A Delaware federal court found that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patents were invalid, strengthening the competitive position of UTHR’s Tyvaso franchise. United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
• Positive Sentiment: The ruling could restrict Yutrepia’s use in the PH-ILD market and potentially support a request for the FDA to withdraw or limit that indication until revised labeling is approved. Investors are viewing the decision as a potential extension of Tyvaso’s market protection and future cash-flow durability. UTHR Prevails in LQDA’s Yutrepia Patent Dispute
• Positive Sentiment: Analyst sentiment remains broadly constructive, with some firms maintaining targets well above the current share price. The company’s patent win and the resulting collapse in Liquidia shares reinforced expectations of reduced competitive pressure. United Therapeutics Stock Rises Following Federal Court Patent Victory
• Neutral Sentiment: The legal outcome may still face appeals, additional proceedings, or regulatory review, so the timing and financial impact of any restrictions on Yutrepia remain uncertain. Analysts also have conflicting views, ranging from a bullish $687 target to a bearish $321 target, highlighting valuation and execution risk. Analysts Have Conflicting Sentiments on Healthcare Companies
• Negative Sentiment: Insider selling provides a counterpoint: CEO Martine Rothblatt sold a combined 9,500 shares, while EVP Paul Mahon sold 8,300 shares worth approximately $4.7 million. These sales may reflect scheduled trading plans, but continued insider selling could weigh on sentiment. United Therapeutics Insider Selling

United Therapeutics Trading Down 4.1%

The stock has a 50 day moving average of $510.03 and a 200-day moving average of $539.64. The company has a market capitalization of $23.51 billion, a P/E ratio of 19.71, a P/E/G ratio of 2.72 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the company earned $6.41 EPS. United Therapeutics’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Callan Family Office LLC purchased a new stake in United Therapeutics during the second quarter valued at $1,217,000. Nicholas Investment Partners LP increased its holdings in shares of United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after buying an additional 3,766 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at about $3,359,000. Havemeyer Place LP bought a new position in shares of United Therapeutics in the 4th quarter valued at about $2,189,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of United Therapeutics in the 4th quarter valued at about $633,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.